Evidence map›Paper›PMID 38868307›Full record

ArticleOpen forum infectious diseases2024

Severe Mpox Among People With Advanced Human Immunodeficiency Virus Receiving Prolonged Tecovirimat in New York City.

Elizabeth A Garcia, Mary M K Foote, Tristan D McPherson, Maura K Lash, Amma N Bosompem, Alyssa Bouscaren, Justin Chan, Madeline A DiLorenzo, Dennis Feihel, Randal C Fowler and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Tecovirimat for the Treatment of Mpox.The New England journal of medicine · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Elizabeth A GarciaDivision of Disease Control, New York City Department of Health and Mental Hygiene, Queens, New York, USA.ORCID https://orcid.org/0000-0002-3453-2625
Mary M K FooteDivision of Disease Control, New York City Department of Health and Mental Hygiene, Queens, New York, USA.
Tristan D McPhersonDivision of Disease Control, New York City Department of Health and Mental Hygiene, Queens, New York, USA.
Maura K LashDivision of Disease Control, New York City Department of Health and Mental Hygiene, Queens, New York, USA.
Amma N BosompemHuman Resources Administration, New York City Department of Social Services, New York, New York, USA.
Alyssa BouscarenDepartment of Homeless Services, New York City Department of Social Services, New York, New York, USA.
Justin ChanDivision of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, New York, USA.ORCID https://orcid.org/0000-0002-0056-8224
Madeline A DiLorenzoDivision of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, New York, USA.
Dennis FeihelLenox Hill Hospital Department of Medicine, Northwell Health, New York, New York, USA.
Randal C FowlerDivision of Disease Control, New York City Department of Health and Mental Hygiene, Queens, New York, USA.
Vani GandhiDivision of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Elizabeth R Jenny-AvitalDivision of Infectious Diseases, NYC Health + Hospitals/Jacobi, Bronx, New York, USA.
Erik J KoppingDivision of Disease Control, New York City Department of Health and Mental Hygiene, Queens, New York, USA.
Dana MazoDivision of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, New York, USA.ORCID https://orcid.org/0000-0002-9304-6563
Jacob McLeanDivision of Infectious Diseases, New York Presbyterian Hospital, Columbia University, New York, New York, USA.
Ofole MgbakoDivision of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, New York, USA.
Mark N SayeghDivision of Infectious Diseases, NYC Health + Hospitals/Harlem, New York, New York, USA.
Raphael N ShawDivision of Infectious Diseases, NYC Health + Hospitals/Harlem, New York, New York, USA.
Michelle SuDivision of Disease Control, New York City Department of Health and Mental Hygiene, Queens, New York, USA.
Jeanne Sullivan MeissnerDivision of Disease Control, New York City Department of Health and Mental Hygiene, Queens, New York, USA.
Jade C WangDivision of Disease Control, New York City Department of Health and Mental Hygiene, Queens, New York, USA.
Wendy WenDivision of Disease Control, New York City Department of Health and Mental Hygiene, Queens, New York, USA.
John C WintersDivision of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Cosmina B ZeanaDivision of Infectious Diseases, BronxCare Health System, Bronx, New York, USA.
Jason ZuckerDivision of Infectious Diseases, New York Presbyterian Hospital, Columbia University, New York, New York, USA.ORCID https://orcid.org/0000-0001-6987-6412
Marcia WongDivision of Disease Control, New York City Department of Health and Mental Hygiene, Queens, New York, USA.

Funding

Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
Columbia Collaborative HIV/AIDS Clinical Trials UnitU01AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HAMMER, SCOTT M · 2007 to 2011
$15.4M
Columbia Integrated Training Program in Infectious Diseases ResearchT32AI100852 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK, Anne-Catrin Uhlemann · 2013 to 2026
$2.2M
NIAID NIH HHS T32 AI100852NIAID NIH HHS U01 AI069470NIAID NIH HHS UM1 AI069470
6 · The paper itself

Abstract

Severe mpox has been observed in people with advanced human immunodeficiency virus (HIV). We describe clinical outcomes of 13 patients with advanced HIV (CD4 <200 cells/μL), severe mpox, and multiorgan involvement. Despite extended tecovirimat courses and additional agents, including vaccinia immune globulin, cidofovir, and brincidofovir, this group experienced prolonged hospitalizations and high mortality.

Indexed as

HIV/AIDSimmunocompromisemortalitympox treatmenttecovirimat

Identifiers

PMID38868307
PMCPMC11168585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.